Hyperthermia payment boost
This article was originally published in The Gray Sheet
CMS proposes to raise reimbursement for procedure codes applicable to BSD Medical's cancer treatment systems by 86% in the 2008 hospital outpatient payment 1proposal released July 16, according to the firm. CMS will finalize the rates in November, to be effective Jan. 1. BSD markets hyperthermia systems, which kill cancer cells with focused heat and may improve the effectiveness of radiation and chemotherapy by increasing blood flow. The firm filed a response July 30 to questions FDA had on its March PMA submission for the BSD-2000 deep hyperthermia system, providing new data from a Dutch study with 12-year follow-up of patients treated with advanced cervical cancer (2"The Gray Sheet" Jan. 9, 2006, p. 15)...
You may also be interested in...
BSD Medical plans to submit a PMA application by the end of the quarter for its non-invasive BSD-2000 tumor hyperthermia therapy system to treat cancer
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.